Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Foundations of Disease > Exam 2: Platelets and Coagulation > Flashcards

Exam 2: Platelets and Coagulation Flashcards

1
Q

Platelet

Functions

A
  • Limit bleeding after injury to a blood vessel
  • Promote vessel repair
  • Regular maintenance of an intact endothelium
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Platelet Count

A

Normal range: 150,000 - 450,000 platelets/microliter

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Thrombocytopenia

A
  • Abnormally low platelet count
    • < 150,000/microliter
  • Characterized by:
    • Easy bruising
    • Nose bleeds
    • Petechial rash
    • Spontaneous bleeding
      • Occurs below 20,000 platelets/microliter
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Idiopathic Thrombocytopenic Purpura

(ITP)

A

Autoimmune disease where anti-platelet Ab destroy platelets.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Platelet

Lifecycle

A
  • Derived from bone marrow cells called megakaryocytes
  • Lifespan ~ 8-10 days
  • Removed by sleen or via clotting process
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Platelet

Morphology

A

Small, flat, disc-shaped membrane-enclosed bits of cytoplasm.

Hyalomere

  • Clear outer region
  • Contains bundles of microtubules
    • Helps maintain discoid shape
  • Contains actin & myosin
    • Involved in shape change of activated platelets

Granulomere

  • Central region with basophilic stippling
  • Contains usual cytoplasmic organelles
  • Contains at least 3 types of granules
    • Alpha, Delta, and Lambda

2 systems of membrane bound channels:

  • Open canalicular system
    • Invaginations of the plasma membrane
    • Facilitates rapid exocytosis of granules
  • Dense tubular system
    • Stores Ca2+ needed for exocytosis
    • Not continuous with the plasma membrane
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Alpha (α) Granules

A

Contains:

Platelet-derived growth factor (PDGF) ⇒ mitogen for vessel repair

von Willebrand Factor (vWF) ⇒ mediates platelet adhesion to endothelium (collagen and laminin)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Delta (δ) Granules

A

Contains:

Ca2+, ATP, ADP ⇒ all enhance platelet aggregation

Serotonin ⇒ vasoconstriction

(Picked up by platelets in circulation)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Lambda (λ) Granules

A

Contains:

Lysosomal enzymes ⇒ clot resorption

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Vessel Repair

Process

A

Adhesion

  • vWF binds to components of the damaged basement membrane (collagen, laminin)
    • vWF can be secreted by many cells including platelets
  • vWF attracts platelets which have surface receptor for vWF
  • Single layer of platelets forms @ site of endothelial damage

Aggregation

  • Adhered platelets secrete fibrinogen
  • Other platelets attracted to the site via cell surface receptors for fibrinogen
  • Fibrinogen links the platelets together
  • Forms a multilayered primary hemostatic plug
    • Fills the defect in the vessel wall

Activation

  • Aggregation causes platelet activation
  • Results in:
    • Secretion of granule mediators
    • Synthesis and release of aracidonic acid derivatives
      • Thromboxane A2 (TXA2)
    • ​Change of platelet shape
      • Mediated by the hyalomere
  • Released mediators cause:
    • Further platelet aggregation
      • TXA2, serotonin, and Ca2+
    • Vasoconstriction (limits bleeding)
      • Serotonin and TXA2
    • Blood coagulation
      • Platelets release several coagulating factors from α-granules
      • Meshwork of fibrin formed which stabilizes the platelet plug forming the secondary hemostatic plug

Clot Retraction

  • After ~ 1 hr, platelets contract due to actin-myosin interaction
    • Platelet plug ↓ in size & flattens against vessel wall
    • Helps to re-establish smooth blood flow

Clot Resorption

  • Mediated partially by lysosomal enzymes from λ-granules

Vessel Repair

  • Mediated by platelet-derived growth factor (PDGF) from α-granules
  • PDGF is strongly mitogenic for cells needed to rebuild the vessel wall including:
    • Endothelial cells
    • Fibroblasts
    • Smooth muscle
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Platelet Activation

Regulation

A
  • Platelets activated upon binding to collagen and laminin of damaged basement membrane
    • Not exposed in healthy vessels
  • Healthy endothelial cells produce factors that inhibit platelet aggregation
    • Ex. Prostacyclin I2 (PGI2) from arachidonic acid
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Aspirin

A

Inhibits cyclooxygenase activity

  • ↓ platelet function
  • Prolongs bleeding times
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Thrombosis

A

Formation of a clot (thrombus)

  • Can cause serious damage
  • Can lead to death if vessel occluded
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Thrombus

Charactertistics

A
  • Meshwork of fibrin + plug of activated platelets
  • Clotting occurs in association with membranes
  • Pathology:
    • In coronary arteries ⇒ MI
    • In cerebral arteries ⇒ ischemic stroke
    • In peripheral arteries ⇒ claudication (leg pain with exercise) or amputation
    • In deep veins ⇒ DVT
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Embolus

A

A mass traveling through the circulation.

Can be a thrombus broken off a site of coagulation.

If thrombus lodges in the lung ⇒ pulmonary embolism (PE)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Blood Clotting

Overview

A

Initiated on the membranes of endothelial cells and platelets:

  1. Formation of a fibrin clot
  2. Formation of a platelet plug
  3. Vasoconstriction (eicosanoids, PGs, Txs)
  4. Limits to the process (anticoagulation)
  5. Clot dissolution (fibrinolysis)
  6. Wound repair

Functions through cascade of proteolytic cleavage or conformational changes.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Fibrin Clot Formation

Charactertistics

A
  • Intrinsic and extrinsic pathways converge on the final common pathway
  • Major factors
    • Named by Roman numerals & common names
      • Factor IX = Christmas factor
    • Are glycoproteins synthesized primarily by the liver
  • Functions using cascades
    • Activation primarily by proteolytic cleavage
    • Successive proteins are serine proteases
      • Cleaves peptide bond on carboxyl side of Arg or Lys
    • Activation can also be caused by conformational changes
    • Facilitates acceleration and amplification of process
  • Non-proteolytic proteins also needed ⇒ accessory proteins (cofactors)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Clotting Effectors

A

Presence accelerates the rate of certain steps in fibrin clot formation:

  • Negatively charged phospholipids (PS, PI)
    • Normally found on inner leaflet of plasma membrane
    • Exposure signals injury
  • Ca2+
    • Binds negatively charged γ-carboxyglutamate (Gla) residues on certain clotting proteins
    • Facilitates binding of these proteins to exposed negatively charged phospholipids
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Gla Proteins

A

Factors II, VII, IX, X

  • Contains negatively charged γ-carboxyglutamate (Gla) residues
  • γ-carboxylation
    • Post-translational modification
      • 9-12 Glu residues @ N-terminus carboxylated to Gla residues by glutamyl carboxylase
    • Occurs in lumen of RER in hepatocytes
    • Vit K required as co-enzyme
      • Oxidized in reaction to epoxide
      • Must be reduced back to hydroquinone form to continue
        • Done by Vitamin K epoxide reductase (VKOR)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Dicumarol

&

Warfarin (Coumadin)

A

⊗ reduction of Vit K by VKOR

  • Inhibits clotting by depleting pool of Vit K
  • Oral administration
    • Slow onset
    • Long half-life
  • Polymorphisms in cytochrom P450 and VKOR isozymes results in varied dosing
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Tissue Factor

(TF)

A
  • Transmembrane glycoprotein
    • Abundant in vascular subendothelium
  • Released by damaged tissue ⇒ extravascular
  • Key protein in the extrinsic pathway
    • Pathway is quickly shut down by tissue factor pathways inhibitors (TFPI)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Extrinsic Pathway

A

“Tissue Factor Pathway”

  1. Vascular injury exposes extravascular TF (Factor III) to Factor VII
  2. TF binding causes conformation change of VII activating it to VIIa
    • VII can also be activated by Factor XIIa from intrinsic path or thrombin (IIa) from common path
  3. VIIa is a serine protease which activates factor X
  4. Factor Xa enters the common pathway

Extrinsic pathway is quickly shut down by tissue factor pathway inhibitors (TFPI).

23
Q

Intrinsic Pathway

A

“Contact Pathway”

All protein factors are found in the blood ⇒ intravascular

Contact Phase

Results in the activation of factor XII → XIIa

  1. Contact of blood with a negatively charged surface ⇒ conformational change & activation of factor XII → XIIa
    • In vitro ⇒ glass blood vials
      • Sodium citrate/oxalate added to chelate Ca2+ and prevent clotting
    • In vivo ⇒ ⊖ PL on damaged endothelium or an abnormal surface
      • E.g. mechanical heart valve, stent, knee/hip replacements
  2. Amplification of contact phase
    • Factor XIIa cleaves Prekallikrein-HMWK at an anionic surface producing Kallikrein
      • HMWK = High molecular weight kininogen
    • Kallikrein can then proteolytically cleave additional Factor XII ⇒ amplification

No known bleeding disorders associated with factor deficiencies of the contact phase.

X Activation Phase

  1. Factor XIIa cleaves XI-HMWK at an anionic surface to produce Factor XIa
    • Factor XI can also be activated by Thrombin from common pathway
    • Defective Factor XI → Hemophilia C
  2. Factor XIa cleaves Factor IX (Christmas factor) → IXa
    • Defective Factor IX → Hemophilia B
    • Can also be cleaved by Factor VIIa from extrinsic pathway
  3. Factor IXa combines with Factor VIIIa
    • Interaction with VIIIa ↑↑↑ rxn rate
    • Factor VIII found in the blood bound to von Willebrand factor (vWF)
      • vWF protects VIII from degradation
      • Thrombin from common pathway cleaves vWF off VIII activating it
    • Defective Factor VIII → Hemophilia A
  4. IXa:VIIIa complex cleaves Factor X → Xa
    • Factors VIIIa, IXa, 10, and Ca2+ on membrane ⇒ Tenase complex
24
Q

Hemophilia

A
  • Coagulopathy caused by clotting factor deficiencies
    • Factor VIII ⇒ Hemophilia A
      • 6x more common than B
      • Found on chromosome Xq
    • Factor IX ⇒ Hemophilia B
      • Found on chromosome Xq
    • Factor XI ⇒ Hemophilia C
      • Autosomal recessive
  • Manifestations
    • Decreased/delayed ability to clot
    • Formation of abnormally friable clots
  • Severity related to residual activity
    • Effects seen if < 30% activity
    • Severe form if < 1% activity
      • Spontaneous, prolonged bleeding particularly into joints and muscle
  • Treatment
    • Recombinant factor replacement
    • Somatic gene therapy in development
25
Q

Common Pathway

A

Factor Xa to Fibrin:

  1. Factor Xa from both intrinsic and extrinsic paths associates with Factor Va(accessory protein) forming Xa-Va ⇒ Prothrombinase complex
    • Binding of Va ⇒ 20x ↑ in Xa activity
  2. Binding of Ca2+ to Gla residue on Prothrombin (Factor II) facilitates binding of Prothrombin to membrane and to Xa-Va complex
  3. Xa-Va complex cleaves Prothrombin (II) → Thrombin (IIa)
    • Excises Gla region releasing Thrombin from the membrane
      • Only time Gla excised
      • Gla-peptide remains bound to membrane surface
        • Taken up by the liver
  4. Thrombinplasma cleaves Fibrinogen (Factor I) → Fibrin (Ia)
  5. Fibrin forms the fibrin soft clot
  6. Thrombinplasma activates Factor XIII → XIIIa
  7. Factor XIIIa (transglutaminase) cross-links Gln from one fibrin with Lys of another ⇒ isopeptide bond
    • Converts soft clot into an insoluble hard clot
26
Q

Fibrin

A
  • Fibrinogen
    • Soluble glycoprotein made by the liver
    • Dimers of three different polypeptides held together at N-termini by disulfide bonds
  • N-termini of the chains form “tufts” on the central three globular domains (D, E, D)
  • Thrombin cleaves the negatively charged tufts producing fibrinopeptides:
    • Fibrinogen → fibrin monomers
    • Solubility decreases
    • Fibrin monomers associate laterally
    • Soft fibrin clot formed
27
Q

Roles of Thrombin

A
28
Q

Blood Clotting

Complete Pathway

A

Pathway Interconnections:

  • Factor VIIa of extrinsic path activates factor IX of intrinsic path
  • Factor XIIa of intrinsic path activates factor VII of extrinsic path
  • Thrombin (IIa) of common path activates factors of intrinsic and extrinsic paths
    • Factors 7, 12, 11, 8, and 5
29
Q

Clotting Factors

Classifications

A
30
Q

Platelet plug provides…

A

primary hemostasis

31
Q

Fibrin net provides…

A

secondary hemostasis

32
Q

Platelet Plug

Formation

A
  1. vWF binds exposed collagen on endothelial surface
  2. Platelets bind:
    • To vWF via GP1b
      • Part of the membrane receptor complex (GP1b/V/IX)
        • vWF made by endothelial cells and megakaryocytes
    • Directly to collagen via GPVI
  3. Binding stops forward movement of platelets causing adherence
  4. Platelet activation causes degranulation
    • Thrombin is the most potent activator
      • Required for platelet activation and fibrin formation
    • Also exposes anionic PL which allows formation of tenase complex on surface of platelets
  5. Conformational Δ following activation leads to platelet aggregation
    • Forms the platelet plug ⇒ primary hemostasis
  6. Conformational Δ in GPIIb/IIIa receptor exposes fibrinogen binding sites
  7. Fibrinogen binds & links activated platelets to one another
    • Fibrinogen → Fibrin by Thrombin (IIa)
    • Cross linkage by Factor XIIIa from plasma and platelets
    • Fibrin net strengthens platelet plug to resist shear forces
      • Achieves secondary hemostasis
33
Q

Platelet Activation

A
  1. Thrombin binds to and activates protease-activated receptors (PARs) on the surface of platelets & endothelial cells
    • Type of Gq receptor
  2. Receptor activates PLC which cleaves PIP2 → DAG and IP3
  3. DAG activates PKC leading to degranulation
  4. IP3 causes release of Ca2+ from delta granules
  5. Calcium causes:
    • Shape changes in platelet
      • Ca2+ activates MLCK which phosphorylates MLC
      • Favors association with actin
    • Activation of PLA2
      • Synthesis of TXA2
        • Platelet degranulation
        • Vasoconstriction
          • Via serotonin
        • Activation of additional platelets
          • By binding to GPCR on platelet membrane
34
Q

Platelet Activation

Regulation

A
  • Vascular wall is separated from blood by endothelial cells
    • Components like collagen and laminin are not exposed
  • Endothelial cells synthesize the vasodilators PGI2 and NO
  • Endothelial cells have a cell surface ADPase that converts ADP → AMP
35
Q

Platelet Degranulation

A

Degranulation releases:

  • Delta granules
    • Serotonin: causes vasocontriction
    • ADP: activates additional platelets
      • Plavix blocks ADP receptors preventing ability to activate platelets
  • Alpha granules:
    • PDGF: helps in wound healing
    • Factor Va
    • vWF
    • Fibrinogen
    • Many more
36
Q

Von Willebrand’s

Disease

A
  • Deficiency of von Willebrand’s factor
  • Results in abnormal platelet adhesion
  • Most common inherited coagulopathy
    • AR
37
Q

Bernard-Soulier

Syndrome

A
  • Deficiency of platelet receptor for von Willebrand’s factor
    • GP1b receptor
  • Results in abnormal platelet adhesion
38
Q

Glanzmann’s Thrombasthenia

A
  • Deficiency of platelet receptor for fibrinogen
    • GPIIb/IIIa complex
  • Results in decreased platelet aggregation
39
Q

Immune thrombocytopenia

A

Autoimmune disorder caused by autoantibodies to platelet receptor for fibrinogen.

40
Q

Pathways of Coagulation

Interrelationships

A
  • TF—VIIa of extrinsic path activates IX of intrinsic path
  • XIIa of intrinsic path activates VII of extrinsic path
  • Thrombin (IIa) of common path activates components of both the intrinsic and extrinsic paths and also activates platelets
  • Tenase complex of intrinsic path forms on the surface of activated platelets and damaged endothelium
  • One fifth of total Va is released by activated platelets
  • XIIIa and vWF present in both plasma and platelets
41
Q

Antithrombin III

(AT-III)

A
  • Made by the liver
  • Serine protease inhibitor (serpin)
  • ATIII binds to and inactivates:
    • Thrombin (most important)
      • Binding makes catalytic domain of thrombin inaccessible
    • Factor IXa through XIIa
      • Inactivation of X is key
    • Factor VIIa-TF complex
  • Complexes removed by liver
  • AT-III : Thrombin binding is greatly increased by heparin
    • Sulfated GAG released by mast cells in response to injury
42
Q

Heparin

A
  • Therapeutically used to ↓ clot formation
  • IV administration
    • Rapid-onset
    • Short half-life
43
Q

Activated Protein C Complex

(APC)

A

Protein C-Protein S complex inactivates Va and VIIIa by proteolysis.

  • Protein C(Gla) activated by thrombin-thrombomodulin complex
    • Thrombomodulin expressed on the surface of undamaged endothelial cells
      • Binds thrombin
      • ↓ thrombin’s affinity for fibrinogen
      • ↑ thrombin’s affinity for Protein C
  • Protein C complexes with Protein S(Gla) ⇒ activated Protein C complex (APC)
  • APC cleaves Va and VIIIa
    • Protein S helps achor Protein C to the clot
44
Q

Tissue Factor Pathway Inhibitor

(TFPI)

A

Protein that inhibits the extrinsic pathway shortly after its activation.

Intrinsic path becomes dominant.

45
Q

Fibrinolysis

A
  • Plasminogen binds to fibrin & incorporated into clots during formation
  • Physiological activators of plasminogen bind and cleave plasminogen → plasmin
    • Tissue plasminogen activator (t-PA or TPA)
      • Made by endothelial cells
      • Secreted in inactive form in response to thrombin
      • Becomes active when bound to fibrin-plasminogen
    • Urokinase (u-PA)
      • Made in the kidney
  • Plasmin hydrolyzes fibrin clot
    • Bound plasmin and TPA protected from inhibitors
    • When fibrin clot is dissolved, they are exposed and inactivated
      • α-2 antiplasmin ⇒ ⊗ plasmin
      • PAI (plasminogen activator inhibitor) ⇒ ⊗ TPA
46
Q

Plasmin

A
  • Serine protease which degrades fibrin
  • Plasminogen made by the liver & released into the blood
  • Binds to fibrin and is incorportated into clots as they are formed
  • Activated by TPA or u-PA
47
Q

Therapeutic Fibrinolysis

A

Treat patients with TPA or u-PA

48
Q

Thrombophilia

A

“Hypercoagulability”

Caused by:

  • Factor V Leiden
  • G20210A prothrombin gene mutation
    • ↑ factor II activity
    • Most prevalent genetic risk factor for venous thrombosis in Spanish populations
  • Deficiencies of proteins C, S, and ATIII
  • Excess lipoprotein A
  • Hyperhomocysteinemia
  • Anti-phospholipid Ab ⇒ referred to as Lupus anticoagulant
49
Q

Factor V Leiden

A
  • Mutant form of factor V ⇒ resistant to APC cleavage
  • Most commonly inherited thrombophilic condition
    • Esp. Caucasians, specifically Scandinavians
  • Heterozygotes have a 7x increased risk of forming clots
  • Homozygotes have 80x increased risk
50
Q

Virchow’s Triad

A

Three broad categories thought to contribute to thrombophilia:

51
Q

Coagulation

Summary

A
  • Tissue injury ⇒ blood vessel damage ⇒ collagen exposure
  • Platelets bind collagen
    • Mediated by vWF
  • Platelet activation
    • Thrombin is key
  • Platelet degranulation and synthesis of arachidonic acid products
    • Vasoconstriction
    • Platelet recruitment
    • Support the clotting cascade
  • Factors of intrinsic, extrinsic, and common paths of clotting cascade + Ca2+ + anionic surface ⇒ fibrin clot formation
    • Initial platelet plug ⇒ primary hemostasis
    • Fibrin mesh ⇒ secondary hemostasis
  • Clotting limited to injured site
    • Proteins that inactivate thrombin ⇒ AT-III, heparin
    • Proteins that degrade V & VIII ⇒ APC
  • After wound is healed, fibrin clot degraded by plasmin
    • Plasmin inactivated by α-2 antiplasmin
    • TPA inactivated by PAI
52
Q

Abnormal Clotting

Summary

A

Disorders of vessels, platelets, and coagulation proteins ⇒ deviations in ability to clot.

  • Vessels
    • Scurvy
    • Plaque formation
    • Hyper-Hcy
    • ↑ Lp(a)
  • Platelets
    • ↓ number ⇒ thrombocytopenia
    • ↓ function
      • Deficiency of vWF ⇒ VW disease
      • Deficiency of GP1b ⇒ Bernard-Soulier syndrome
      • Deficiency of CPIIb/IIIa ⇒ Glanzmann thrombasthenia
  • Coagulation proteins
    • VIII ⇒ Hemophilia A
    • IX ⇒ Hemophilia B
    • XI ⇒ Hemophilia C
    • Factor V Leiden
53
Q

Clotting

Clinical Tests

A
  • Platelets
    • Platelet counts
    • Platelet function tests
  • Extrinsic through common path
    • Prothrombin time (PT)
      • Uses thromboplastin
        • Combination of PL + TF
      • Expressed as INR (international normalized ratio)
  • Intrinsic through common path
    • Activated partial thromoplastin time (aPTT)
      • Uses partial thromboplastin
        • Just the PL portion b/c TF isn’t needed to activate intrinsic path

Foundations of Disease (46 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions